Prostate Active Surveillance Study
Trial ID or NCT#
NCT00756665
Status
RECRUITING
Purpose
The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.
Official Title
Canary Prostate Active Surveillance Study
Eligibility Criteria
Ages Eligible for Study: Older than 21 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Histologically confirmed adenocarcinoma of the prostate from a prostate biopsy. - Clinically localized prostate cancer: T1-2, NX or N0, MX or M0. - No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy). - ECOG Performance Status 0 or 1. - Patient has elected Active Surveillance as preferred management plan for prostate cancer. - Patient consent has been obtained according to local Institutional Review Board for acquisition of research specimens. - Patient is accessible and compliant for follow-up. - Prostate cancer diagnosis cannot be more than 3 years prior to baseline visit date. - No more than two prostate biopsies including the initial biopsy in which cancer was diagnosed. - If cancer diagnosis is more than one year before enrollment, there must be two prostate biopsies including the initial biopsy in which cancer was diagnosed and a subsequent biopsy. The subsequent biopsy may occur on the same day as the baseline visit. - Biopsies must have at least 10 cores.
Exclusion Criteria:
- - Unwillingness or inability to undergo serial prostate biopsy. - History of other malignancies, except: adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer (Ta) or other solid tumors curatively treated with no evidence of disease for > 5 years.
Investigator(s)
Benjamin I. Chung
Urologic oncologist,
Urologic specialist,
Urologist,
Genitourinary specialist,
Urologic surgeon
Associate Professor of Urology
Harcharan Gill
Urologic oncologist,
Urologist,
Genitourinary specialist,
Urologic surgeon
Kathryn Simmons Stamey Professor, Emeritus
Contact us to find out if this trial is right for you.
Contact
Michelle Ferrari
650-725-5543
View on ClinicalTrials.gov
